Literature DB >> 22727409

Clinical correlates and heritability of erythrocyte eicosapentaenoic and docosahexaenoic acid content in the Framingham Heart Study.

William S Harris1, James V Pottala, Sean M Lacey, Ramachandran S Vasan, Martin G Larson, Sander J Robins.   

Abstract

OBJECTIVES: Red blood cell (RBC) levels of eicosapentaenoic acid (EPA) plus docosahexaenoic acid (DHA, the omega-3 index, expressed as a percent of total fatty acids) are inversely related to risk for cardiovascular disease (CVD). Although several mechanisms underlying this relationship have been proposed, understanding the associations between the omega-3 index and markers of CVD in the community can shed additional light on this question. The objectives of this study were to define the relations between the omega-3 index and clinical factors and to determine the heritability of the omega-3 index.
METHODS: RBC samples (n = 3196) drawn between 2005 and 2008 from participants in the Framingham Study [Examination 8 of the Offspring cohort plus Examination 3 of the Omni (minorities) cohort] were analyzed for fatty acid composition by gas chromatography.
RESULTS: The mean (SD) omega-3 index was 5.6% (1.7%). In multivariable regression models, the factors significantly and directly associated with the omega-3 index were age, female sex, higher education, fish oil supplementation, dietary intake of EPA + DHA, aspirin use, lipid pharmacotherapy, and LDL-cholesterol. Factors inversely associated were Offspring cohort, heart rate, waist girth, triglycerides and smoking. The total explained variability in the omega-3 index for the fully adjusted model was 73%, which included major components due to heritability (24%), EPA + DHA intake (25%), and fish oil supplementation (15%).
CONCLUSION: The variability in the omega-3 index is determined primarily by dietary and genetic factors. An increased omega-3 index is associated with a generally cardioprotective risk factor milieu.
Copyright © 2012 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22727409      PMCID: PMC3593234          DOI: 10.1016/j.atherosclerosis.2012.05.030

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  73 in total

1.  Mediation in experimental and nonexperimental studies: new procedures and recommendations.

Authors:  Patrick E Shrout; Niall Bolger
Journal:  Psychol Methods       Date:  2002-12

Review 2.  n-3 fatty acids in cardiovascular disease.

Authors:  Raffaele De Caterina
Journal:  N Engl J Med       Date:  2011-06-23       Impact factor: 91.245

3.  Changes in erythrocyte membrane trans and marine fatty acids between 1999 and 2006 in older Americans.

Authors:  William S Harris; James V Pottala; Ramachandran S Vasan; Martin G Larson; Sander J Robins
Journal:  J Nutr       Date:  2012-05-23       Impact factor: 4.798

Review 4.  Omega-3 fatty acids and cardiovascular disease: effects on risk factors, molecular pathways, and clinical events.

Authors:  Dariush Mozaffarian; Jason H Y Wu
Journal:  J Am Coll Cardiol       Date:  2011-11-08       Impact factor: 24.094

5.  Association of serum n-3 polyunsaturated fatty acids with C-reactive protein in men.

Authors:  I Reinders; J K Virtanen; I A Brouwer; T-P Tuomainen
Journal:  Eur J Clin Nutr       Date:  2011-11-23       Impact factor: 4.016

6.  Increase in circulating products of lipid peroxidation (F2-isoprostanes) in smokers. Smoking as a cause of oxidative damage.

Authors:  J D Morrow; B Frei; A W Longmire; J M Gaziano; S M Lynch; Y Shyr; W E Strauss; J A Oates; L J Roberts
Journal:  N Engl J Med       Date:  1995-05-04       Impact factor: 91.245

7.  Polyunsaturated fatty acid levels of serum and red blood cells in apparently healthy Japanese subjects living in an urban area.

Authors:  Naotake Yanagisawa; Kazunori Shimada; Tetsuro Miyazaki; Atsumi Kume; Yohei Kitamura; Ryoko Ichikawa; Hirotoshi Ohmura; Takashi Kiyanagi; Makoto Hiki; Kosuke Fukao; Katsuhiko Sumiyoshi; Kuniaki Hirose; Rie Matsumori; Hirotaka Takizawa; Kiyotaka Fujii; Hiroshi Mokuno; Nao Inoue; Hiroyuki Daida
Journal:  J Atheroscler Thromb       Date:  2010-03-13       Impact factor: 4.928

8.  Differences between polyunsaturated fatty acid status of non-institutionalised elderly women and younger controls: a bioconversion defect can be suspected.

Authors:  F Babin; M Abderrazik; F Favier; J P Cristol; C L Léger; L Papoz; B Descomps
Journal:  Eur J Clin Nutr       Date:  1999-08       Impact factor: 4.016

Review 9.  The nutritional and clinical significance of lipid rafts.

Authors:  Parveen Yaqoob; Saame Raza Shaikh
Journal:  Curr Opin Clin Nutr Metab Care       Date:  2010-03       Impact factor: 4.294

10.  Factors influencing EPA+DHA levels in red blood cells in Japan.

Authors:  Miho Itomura; Shuntaro Fujioka; Kei Hamazaki; Kouji Kobayashi; Tetsuro Nagasawa; Shigeki Sawazaki; Yuko Kirihara; Tomohito Hamazaki
Journal:  In Vivo       Date:  2008 Jan-Feb       Impact factor: 2.155

View more
  51 in total

1.  Leveraging summary statistics to make inferences about complex phenotypes in large biobanks.

Authors:  Angela Gasdaska; Derek Friend; Rachel Chen; Jason Westra; Matthew Zawistowski; William Lindsey; Nathan Tintle
Journal:  Pac Symp Biocomput       Date:  2019

2.  Smoking and red blood cell phospholipid membrane fatty acids.

Authors:  H J Murff; H A Tindle; M J Shrubsole; Q Cai; W Smalley; G L Milne; L L Swift; R M Ness; W Zheng
Journal:  Prostaglandins Leukot Essent Fatty Acids       Date:  2016-08-16       Impact factor: 4.006

Review 3.  n-3 Polyunsaturated Fatty Acids and Cardiovascular Disease: Principles, Practices, Pitfalls, and Promises - A Contemporary Review.

Authors:  Richard Kones; Scott Howell; Umme Rumana
Journal:  Med Princ Pract       Date:  2017-11-29       Impact factor: 1.927

4.  Higher RBC EPA + DHA corresponds with larger total brain and hippocampal volumes: WHIMS-MRI study.

Authors:  James V Pottala; Kristine Yaffe; Jennifer G Robinson; Mark A Espeland; Robert Wallace; William S Harris
Journal:  Neurology       Date:  2014-01-22       Impact factor: 9.910

5.  Omega-3 index levels and associated factors in a middle-aged French population: the MONA LISA-NUT Study.

Authors:  A Wagner; C Simon; B Morio; J Dallongeville; J B Ruidavets; B Haas; B Laillet; D Cottel; J Ferrières; D Arveiler
Journal:  Eur J Clin Nutr       Date:  2014-10-22       Impact factor: 4.016

6.  Peripheral Artery Disease Is Associated with a Deficiency of Erythrocyte Membrane n-3 Polyunsaturated Fatty Acids.

Authors:  Joel L Ramirez; Greg J Zahner; Kimberly A Spaulding; Sukaynah A Khetani; Nancy K Hills; Warren J Gasper; William S Harris; Beth E Cohen; S Marlene Grenon
Journal:  Lipids       Date:  2019-03-18       Impact factor: 1.880

Review 7.  Polyunsaturated fatty acids and recurrent mood disorders: Phenomenology, mechanisms, and clinical application.

Authors:  Erik Messamore; Daniel M Almeida; Ronald J Jandacek; Robert K McNamara
Journal:  Prog Lipid Res       Date:  2017-01-06       Impact factor: 16.195

8.  Effect of Omega-3 Acid Ethyl Esters on Left Ventricular Remodeling After Acute Myocardial Infarction: The OMEGA-REMODEL Randomized Clinical Trial.

Authors:  Bobak Heydari; Shuaib Abdullah; James V Pottala; Ravi Shah; Siddique Abbasi; Damien Mandry; Sanjeev A Francis; Heidi Lumish; Brian B Ghoshhajra; Udo Hoffmann; Evan Appelbaum; Jiazhuo H Feng; Ron Blankstein; Michael Steigner; Joseph P McConnell; William Harris; Elliott M Antman; Michael Jerosch-Herold; Raymond Y Kwong
Journal:  Circulation       Date:  2016-08-02       Impact factor: 29.690

9.  PRECISION MEDICINE: FROM DIPLOTYPES TO DISPARITIES TOWARDS IMPROVED HEALTH AND THERAPIES.

Authors:  Dana C Crawford; Alexander A Morgan; Joshua C Denny; Bruce J Aronow; Steven E Brenner
Journal:  Pac Symp Biocomput       Date:  2018

10.  Red blood cell fatty acid levels improve GRACE score prediction of 2-yr mortality in patients with myocardial infarction.

Authors:  William S Harris; Kevin F Kennedy; James H O'Keefe; John A Spertus
Journal:  Int J Cardiol       Date:  2012-10-06       Impact factor: 4.164

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.